Stoke Therapeutics (STOK) Accumulated Expenses (2018 - 2026)

Stoke Therapeutics' Accumulated Expenses history runs 9 years deep, the most recent figure standing at $23.9 million for Q1 2026.

• On a quarterly basis, Accumulated Expenses fell 1.78% year-over-year to $23.9 million in Q1 2026; TTM through Mar 2026 was $23.9 million, a 1.78% decrease from a year earlier, with the FY2025 full-year figure at $14.0 million, down 24.73% from the prior year.
• Accumulated Expenses grew to $23.9 million in Q1 2026 per STOK's latest filing, from $14.0 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $30.1 million in Q3 2025 and bottomed at $1.7 million in Q1 2024.
• The 5-year median for Accumulated Expenses is $13.8 million (2023), against an average of $14.0 million.
• Across the five-year window, Accumulated Expenses tumbled 88.0% in 2024 and jumped 1372.17% in 2025, its largest moves.
• Year by year, Accumulated Expenses stood at $5.8 million in 2022, then jumped by 140.09% to $13.8 million in 2023, then soared by 34.4% to $18.6 million in 2024, then decreased by 24.73% to $14.0 million in 2025, then soared by 71.03% to $23.9 million in 2026.
• Per Business Quant, the three latest STOK Accumulated Expenses figures stand at $23.9 million (Q1 2026), $14.0 million (Q4 2025), and $30.1 million (Q3 2025).